title: Combined anticancer activity of osthole and cisplatin in NCI-H460 lung cancer cells in vitro.
abstract: Drug combination therapies are common practice in the treatment of cancer. Cisplatin is the most active chemotherapeutic agent for lung cancer treatment. Osthole is a natural compound extracted from a number of medicinal plants. To determine whether osthole enhances the anticancer effect of cisplatin in human lung cancer, we treated NCI-H460 cells with osthole alone or in combination with cisplatin and evaluated cell growth and apoptosis using 3-(4,5-dimethyl thiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay, flow cytometry and fluorescence microscopy. The results showed that, in comparison with single agent treatment, the combination of osthole and cisplatin resulted in greater efficacy in growth inhibition and apoptosis induction. Western blot analysis revealed that the combination effect of osthole and cisplatin was due to regulation of the Bcl-2 family proteins. Findings of this investigation suggested that osthole combined with cisplatin is a potential clinical chemotherapeutic approach in human lung cancer.
authors: Department of Respiratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004,  P.R. China.
authors: Xiao-Man
authors: XM
authors: Xu
authors: Yi
authors: Y
authors: Zhang
authors: Dan
authors: D
authors: Qu
authors: Hong-Bo
authors: HB
authors: Liu
authors: Xiu
authors: X
authors: Gu
authors: Guang-Yu
authors: GY
authors: Jiao
authors: Li
authors: L
authors: Zhao
keywords: NCI-H460 cells; apoptosis; cisplatin; osthole
references: Biosci Biotechnol Biochem. 2010;74(7):1430-4
references: 20622464
references: N Engl J Med. 2002 Jan 10;346(2):92-8
references: 11784875
references: J Exp Clin Cancer Res. 2011 Mar 29;30:33
references: 21447176
references: PLoS One. 2012;7(5):e37865
references: 22662241
references: Lung Cancer. 2002 Dec;38 Suppl 4:21-8
references: 12480191
references: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references: 15761078
references: J Exp Clin Cancer Res. 2010 Jul 01;29:87
references: 20594324
references: Integr Cancer Ther. 2011 Dec;10(4):359-67
references: 21382957
references: Toxicol Appl Pharmacol. 2012 May 15;261(1):105-15
references: 22503731
references: Mol Med Rep. 2012 Nov;6(5):1018-22
references: 22923177
references: Crit Rev Oncol Hematol. 2007 Jul;63(1):12-31
references: 17336087
references: Mol Cancer Ther. 2010 Oct;9(10):2665-75
references: 20937593
references: Phytother Res. 2007 Mar;21(3):226-30
references: 17154232
references: J Agric Food Chem. 2011 Sep 14;59(17):9683-90
references: 21806057
references: Hum Cell. 1988 Sep;1(3):301-7
references: 2979207
references: Nat Clin Pract Oncol. 2007 Oct;4(10):570-7
references: 17898807
references: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references: 18287387
references: Cancer Lett. 2011 May 1;304(1):21-32
references: 21333438
references: J Exp Clin Cancer Res. 2009 Aug 08;28:110
references: 19664237
references: Restor Neurol Neurosci. 2005;23(1):1-9
references: 15846027